Y-mAbs Therapeutics (NASDAQ:YMAB) Downgraded by BidaskClub to Sell

0
38
Close-up shot of senior man counting large group of Turkish Lira Banknotes. Horizontal shot.

Y-mAbs Therapeutics stock has undergone multiple analysts rating changes in the recent past.  Y-mAbs Therapeutics Downgraded by BidaskClub on 7/10/2020. In a note to investors, the firm issued a new rating of Sell. The analysts previously had rating of Hold.

Shares of Y-mAbs Therapeutics traded up $0.33 on Friday, reaching $40.74. 5213 shares of the stock traded hands, compared to its average volume of 273093. Shares of Y-mAbs Therapeutics were trading at $40.74 on Friday. The firm’s 50 day moving average is $41.12 and its 200 day moving average is $32.32.Y-mAbs Therapeutics  has a 12 month low of $39.95 and a 12 month high of $50.49. While on yearly highs and lows, Y-mAbs Therapeutics’s today has traded high as $40.74 and has touched $39.95 on the downward trend. See More Analyst Rating at: RATING

Y-mAbs Therapeutics Earnings and What to expect: 

Y-mAbs Therapeutics last announced its quarterly earnings results on May 7th, 2020. The reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by $0.04. Y-mAbs Therapeutics has generated ($2.30) earnings per share over the last year. Y-mAbs Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Wednesday, August 12th, 2020 based off prior year’s report dates.

Earnings for Y-mAbs Therapeutics are expected to grow in the coming year, from ($2.67) to ($0.35) per share. The P/E ratio of Y-mAbs Therapeutics is -16.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Y-mAbs Therapeutics is -16.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Y-mAbs Therapeutics has a P/B Ratio of 8.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Latest Insiders Trading and Volume : 

  • Insider Ownership Percentage: 38.40%
  • On 6/15/2020 Chairman Thomas Gad Sell 4,000 at average share price of $43.45 which equates to $173,800.00 in money value.
  • On 6/4/2020 Chairman Thomas Gad Sell 4,000 at average price of  $41.61 with total value of : Not Data Available
  • On 5/26/2020 VP Mahiuddin Ahmed Sell 50,000 at average price of  $39.38 with total value of : $1,969,000.00

Other owners latest trading in Y-mAbs Therapeutics :

  • On 6/19/2020 shares held by State Street Corp were 788,395 which equates to market value of $20.58M and appx 0.00% owners of Y-mAbs Therapeutics
  • On 6/15/2020 shares held by AXA were 242,280 which equates to market value of $6.32M and appx 0.00% owners of Y-mAbs Therapeutics
  • On 6/1/2020 shares held by Rice Hall James & Associates LLC were 63,628 which equates to market value of $1.66M and appx 0.10% owners of Y-mAbs Therapeutics
  • In total Institutional ownership equates to Institutional Ownership Percentage: 50.47% for Y-mAbs Therapeutics

Analyst at BidaskClub are also talking about :

  • 7/10/2020 – Zogenix was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 7/10/2020 – Zillow Group was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 7/10/2020 – Xperi was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 7/10/2020 – Xenon Pharmaceuticals was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.

Y-mAbs Therapeutics (NASDAQ:YMAB) Moving Average Technical Analysis

5 day Moving Average is $41.67 And 5 day price change is -$1.67 (-3.97%)  with average volume for 5 day average is 143,120. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $44.78 and 20 day price change is -$2.64 (-6.13%) and average 20 day moving volume is 273,565. 50 day moving average is $41.12  and 50 day price change is $6.71 ( 19.91%)  and with average volume for 50 days is : 273,610. 200 day moving average is $32.32  and 200 day price change is $9.46 (30.57%)  and with average volume for 200 days is : 245,104.

See More Analyst Rating at: RATING